Repligen Corporation

RGEN

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Perceptive Advisors RTW Investments Deerfield Management

Catalysts

No catalysts tracked.

Position Details

Perceptive AdvisorsNEWFeb 17, 2026

Shares: 315,541Value: $51.7M

# Signal Note: Perceptive Initiates RGEN Position Perceptive Advisors' $51.7M entry into Repligen signals conviction in the biotech's core business—the company is a leading supplier of filtration and chromatography systems for biopharmaceutical manufacturing, not a clinical-stage drug developer. The position likely reflects confidence in secular tailwinds (biosimilar adoption, cell therapy manufacturing scale-up) and RGEN's recurring revenue model rather than a near-term clinical catalyst. With Edelman's track record backing clinical programs, this appears to be a pure-play bet on manufacturing infrastructure demand in the expanding biologics sector.

RTW InvestmentsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX3 funds SYRE3 funds COGT3 funds ISRG3 funds KYMR3 funds BLTE3 funds BBNX3 funds IRON

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# RTW Investments Initiates $174M RGEN Position Wong's significant new stake in Repligen signals confidence in the company's bioprocess solutions portfolio, which benefits from sustained demand in cell and gene therapy manufacturing—a secular tailwind as more advanced therapies move toward commercialization. The entry size (1.06M shares, ~3.4% of outstanding) suggests conviction in RGEN's recurring revenue model and margin expansion potential, particularly as its chromatography and filtration platforms become standard manufacturing infrastructure across the biopharma industry.